FTC sues to block Amgen acquisition of Horizon Therapeutics

[ad_1] The Federal Trade Commission on Tuesday filed a lawsuit seeking to block drug giant Amgen‘s $27.8 billion acquisition of Horizon Therapeutics, arguing that the deal would “stifle competition” in the pharmaceutical industry. The FTC said that the deal would allow Amgen to “entrench the monopoly positions” of two of Horizon’s fast-growing medications: the thyroid…

Read More